British medicines regulator approves GSK's new RSV vaccine

10 July 2023
gsk_london_hq

UK-based drugmaker GSK (LSE: GSK) has secured approval in its home country for the breakthrough respiratory syncytial virus (RSV) vaccine, Arexvy (respiratory syncytial virus vaccine).

The Medicines and Healthcare products Regulatory Agency (MHRA) has given its blessing for GSK to market the product for active immunization of people over the age of 60.

The vaccine is used to prevent lower respiratory tract disease caused by RSV, a common virus that leads to an estimated 175,000 visits to the doctor and up to 8,000 deaths among older people in the UK each year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical